Feng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Feng Li has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Chang Shu
Department of Dermatology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College Beijing People's Republic of China
2 shared publications - Chenyu Zhu
Department of Dermatology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College Beijing People's Republic of China
2 shared publications - Qiuning Sun
Department of Dermatology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College Beijing People's Republic of China
2 shared publications Anna Mandinova
Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
1 shared publication- Catherine A. A. Lee
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
1 shared publication - Christine Guo Lian
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
1 shared publication
Latest Publications
- Open Access
- 19 March 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (3) , e70799
Clinical Efficacy of Tofacitinib in Treating Granulomatous Reaction After Mesotherapy: A Case Series Analysis
Background: Mesotherapy, a widely utilized minimally invasive cosmetic procedure, carries potential risks of adverse reactions due to non‐standardized protocols and overuse. Delayed granulomatous reactions represent a chronic complication, imposing significant physical and psychological burdens on patients. Objective: This case series aims to evaluate the efficacy and safety of tofacitinib in managing non‐infectious granulomatous reactions following mesotherapy. Methods: This retrospective analysis included six patients diagnosed with non‐infectious granulomatous reactions post‐mesotherapy, treated at Peking Union Medical College Hospital between October 2021 and April 2025. All patients received oral tofacitinib. Clinical outcomes, treatment regimens, and safety profiles were assessed. Results: All six patients demonstrated significant improvement in skin lesion severity, with no treatment‐related adverse events observed during follow‐up. Conclusion: Oral tofacitinib exhibits promising clinical efficacy and a favorable safety profile for non‐infectious granulomatous reactions induced by mesotherapy, positioning it as a viable therapeutic option during the inflammatory phase.
- 19 March 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (3) , e70799
Open AccessClinical Efficacy of Tofacitinib in Treating Granulomatous Reaction After Mesotherapy: A Case Series Analysis
Background: Mesotherapy, a widely utilized minimally invasive cosmetic procedure, carries potential risks of adverse reactions due to non‐standardized protocols and overuse. Delayed granulomatous reactions represent a chronic complication, imposing significant physical and psychological burdens on patients. Objective: This case series aims to evaluate the efficacy and safety of tofacitinib in managing non‐infectious granulomatous reactions following mesotherapy. Methods: This retrospective analysis included six patients diagnosed with non‐infectious granulomatous reactions post‐mesotherapy, treated at Peking Union Medical College Hospital between October 2021 and April 2025. All patients received oral tofacitinib. Clinical outcomes, treatment regimens, and safety profiles were assessed. Results: All six patients demonstrated significant improvement in skin lesion severity, with no treatment‐related adverse events observed during follow‐up. Conclusion: Oral tofacitinib exhibits promising clinical efficacy and a favorable safety profile for non‐infectious granulomatous reactions induced by mesotherapy, positioning it as a viable therapeutic option during the inflammatory phase.
- Open Access
- 26 June 2023
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1162873
Clinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis
Background: Assessment of therapeutic response of psoriasis has relied traditionally on clinical observation, and effective non-invasive tools are desirable.Objectives: To investigate the value of dermoscopy and high-frequency ultrasound (HFUS) in the monitoring of psoriatic lesions treated with biologics.Methods: Patients with moderate-to-severe plaque psoriasis treated with biologics were evaluated by clinical, dermoscopic, and ultrasonic scores at weeks 0, 4, 8, and 12. Clinical scores, including Psoriasis Area Severity Index (PASI) and target lesion score (TLS), were evaluated at representative lesions. Dermoscopy was performed to assess the red background, vessels, and scales on a 4-point scale as well as the presence of hyperpigmentation, hemorrhagic spots, and linear vessels. HFUS was performed to measure the thicknesses of the superficial hyperechoic band and subepidermal hypoechoic band (SLEB). The correlation between clinical, dermoscopic, and ultrasonic evaluation was also analyzed.Results: In total, 24 patients were analyzed and achieved 85.3 and 87.5% reduction of PASI and TLS, respectively, after 12 weeks of treatment. The red background, vessels, and scales scores under dermoscopy were reduced by 78.5, 84.1, and 86.5%, respectively. Some patients developed hyperpigmentation and linear vessels after treatment. Hemorrhagic dots slowly subside over the therapeutic course. Ultrasonic scores were significantly improved with an average reduction of 53.9% in superficial hyperechoic band thickness and 89.9% in SLEB thickness. TLS in the clinical variables, scales in dermoscopic variables, and SLEB in ultrasonic variables decreased the most significantly in the early stage of treatment (week 4) with 55.4, 57.7, and 59.1% (P > 0.05), respectively. Most of the variables, including the red background, vessels, scales, and SLEB thickness, were strongly correlated with TLS. High correlations were also found between the SLEB thickness and the red background or vessels scores, and between the superficial hyperechoic band thickness and the scales scores.Conclusion: Both dermoscopy and HFUS were useful in the therapeutic monitoring of moderate-to-severe plaque psoriasis.
- 26 June 2023
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1162873
Open AccessClinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis
Background: Assessment of therapeutic response of psoriasis has relied traditionally on clinical observation, and effective non-invasive tools are desirable.Objectives: To investigate the value of dermoscopy and high-frequency ultrasound (HFUS) in the monitoring of psoriatic lesions treated with biologics.Methods: Patients with moderate-to-severe plaque psoriasis treated with biologics were evaluated by clinical, dermoscopic, and ultrasonic scores at weeks 0, 4, 8, and 12. Clinical scores, including Psoriasis Area Severity Index (PASI) and target lesion score (TLS), were evaluated at representative lesions. Dermoscopy was performed to assess the red background, vessels, and scales on a 4-point scale as well as the presence of hyperpigmentation, hemorrhagic spots, and linear vessels. HFUS was performed to measure the thicknesses of the superficial hyperechoic band and subepidermal hypoechoic band (SLEB). The correlation between clinical, dermoscopic, and ultrasonic evaluation was also analyzed.Results: In total, 24 patients were analyzed and achieved 85.3 and 87.5% reduction of PASI and TLS, respectively, after 12 weeks of treatment. The red background, vessels, and scales scores under dermoscopy were reduced by 78.5, 84.1, and 86.5%, respectively. Some patients developed hyperpigmentation and linear vessels after treatment. Hemorrhagic dots slowly subside over the therapeutic course. Ultrasonic scores were significantly improved with an average reduction of 53.9% in superficial hyperechoic band thickness and 89.9% in SLEB thickness. TLS in the clinical variables, scales in dermoscopic variables, and SLEB in ultrasonic variables decreased the most significantly in the early stage of treatment (week 4) with 55.4, 57.7, and 59.1% (P > 0.05), respectively. Most of the variables, including the red background, vessels, scales, and SLEB thickness, were strongly correlated with TLS. High correlations were also found between the SLEB thickness and the red background or vessels scores, and between the superficial hyperechoic band thickness and the scales scores.Conclusion: Both dermoscopy and HFUS were useful in the therapeutic monitoring of moderate-to-severe plaque psoriasis.
- 1 June 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (6) , 1266-1275.e3
Loss of the Epigenetic Mark 5-hmC in Psoriasis: Implications for Epidermal Stem Cell Dysregulation
- 1 June 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (6) , 1266-1275.e3
Loss of the Epigenetic Mark 5-hmC in Psoriasis: Implications for Epidermal Stem Cell Dysregulation